Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026

This reads more like a reimbursement/market-structure signal than a company-specific earnings catalyst. In anti-VEGF, the first-order winner from stronger real-world biosimilar evidence is payers and large retina practices that can steer volume to the lowest net-cost option; the first-order loser is the branded originator ecosystem, which faces slower price realization and more aggressive contracting. For HROW, the key question is whether it monetizes ophthalmology through product mix and channel economics or simply benefits from broader treatment access — because biosimilar adoption can either expand procedure volume or compress the spread on high-ASP therapies depending on where Harrow sits in the value chain.

The market likely underestimates how slowly these effects show up. In the next 1-3 months, the stock reaction should be muted unless management can connect the data to actual formulary wins, prescribing share, or margin lift. Over 6-18 months, the relevant issue is whether biosimilar penetration resets pricing across the retina category and changes buying behavior in physician offices; if so, companies relying on premium pricing or inventory spread will see pressure, while firms with low-cost distribution or adjacent formulations may benefit.

The contrarian view is that conference data alone is not enough to justify a rerating. If the study does not translate into measurable claims-based uptake, this is just a credibility point for the asset, not a P&L event. The thesis would be falsified if HROW’s next quarter shows no evidence that lower-cost retina therapies are improving volume or gross margin, or if payer rebates/originator discounts keep the biosimilar economically irrelevant despite the data.